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One	of	the	main	unresolved	questions	in	solid	organ	transplantation	is	how	to	establish	indefinite	graft	sur-
vival	that	is	free	from	long-term	treatment	with	immunosuppressive	drugs	and	chronic	rejection	(i.e.,	the	
establishment	of	tolerance).	The	failure	to	achieve	this	goal	may	be	related	to	the	difficulty	in	identifying	the	
phenotype	and	function	of	the	cell	subsets	that	participate	in	the	induction	of	tolerance.	To	address	this	issue,	
we	investigated	the	suppressive	roles	of	recipient	myeloid	cells	that	may	be	manipulated	to	induce	tolerance	
to	transplanted	hearts	in	mice.	Using	depleting	mAbs,	clodronate-loaded	liposomes,	and	transgenic	mice	spe-
cific	for	depletion	of	CD11c+,	CD11b+,	or	CD115+	cells,	we	identified	a	tolerogenic	role	for	CD11b+CD115+Gr1+	
monocytes	during	the	induction	of	tolerance	by	costimulatory	blockade	with	CD40L-specific	mAb.	Early	after	
transplantation,	Gr1+	monocytes	migrated	from	the	bone	marrow	into	the	transplanted	organ,	where	they	
prevented	the	initiation	of	adaptive	immune	responses	that	lead	to	allograft	rejection	and	participated	in	the	
development	of	Tregs.	Our	results	suggest	that	mobilization	of	bone	marrow	CD11b+CD115+Gr1+	monocytes	
under	sterile	inflammatory	conditions	mediates	the	induction	of	indefinite	allograft	survival.	We	propose	that	
manipulating	the	common	bone	marrow	monocyte	progenitor	could	be	a	useful	clinical	therapeutic	approach	
for	inducing	transplantation	tolerance.
Introduction
A major goal of clinical organ transplantation is to induce a donor-
specific unresponsive state in a mature immune system that is free 
from long-term immunosuppression and chronic rejection. The 
general failure to reach this goal gives rise to 3 fundamental prob-
lems in clinical transplantation: (a) a high incidence of chronic 
rejection after the fifth year after transplant; (b) continuous need 
for immunosuppression with the risk of multiple side effects and 
opportunistic infections; and (c) discrepancy between the demand 
for and the availability of organs (1). To resolve these problems, 
there is a continuous search for novel therapeutic protocols to 
induce tolerance (2). Unfortunately, although experimental tolero-
genic protocols have proved to induce indefinite allograft survival 
in mice or primates (3, 4), there are additional concerns that pre-
vent translation of these methods into clinical practice (5) and 
underline the need for alternative tolerance-inducing protocols.
Here, we investigated the phenotype and function of various 
cell subsets of myeloid origin that are necessary for the induction 
of long-term allograft survival. One common approach to iden-
tifying the cells that exert a tolerogenic function is to specifically 
deplete cells in vivo and monitor the outcome of the immune 
response in the absence of the targeted cells. In experimental 
transplantation, the use of depletional mAbs and knockout or 
transgenic mouse strains has defined tolerogenic roles for Tregs 
(6), T cells (7), B cells (8), NK cells (9), and NKT cells (10). It is 
noteworthy that although much has been learned about the role 
of lymphocytes using depletional strategies, little is known about 
the outcome of allograft survival in the absence of cells of myeloid 
origin. Indirect evidence for the requirement for recipient myeloid 
cells during transplantation tolerance has been suggested. 
Auchincloss and colleagues reported that under costimulatory 
blockade, transplantation tolerance is not induced in recipients 
that do not express MHC class II in circulating leukocytes, con-
sistent with the necessity of recipient MHC class II+ myeloid cells 
for transplantation tolerance (11).
To investigate the requirement of myeloid cells for the induction 
of transplantation tolerance, vascularized BALB/c donor hearts 
were transplanted into fully allogeneic C57BL/6 recipients, and 
were treated with donor splenocyte transfusion (DST) plus anti-
CD40L mAb for tolerance induction. Using recipient transgenic 
mice that express diphtheria toxin (DT) receptor (DTR) under the 
CD11c or CD11b promoter, together with depletional reagents 
against monocytes, macrophages, and neutrophils, we identified 
CD11b+CD115+Gr1+ monocytes as suppressive cells that inhibit 
the immune response early after transplantation. Using adoptive 
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transfer studies in recipients with reduced numbers of circulating 
CD11b+CD115+Gr1+ monocytes, we further identified the anatom-
ic locations and mechanisms of action by which these cells exert 
their immune regulatory function, which include antigen-non-
specific T cell suppression and development of Tregs. Finally, we 
provided evidence that manipulating the clonogenic bone marrow 
common macrophage/DC precursor (MDP) represents a promis-
ing therapeutic approach for the induction of indefinite allograft 
survival in solid organ transplantation, with concomitant thera-
peutic applications to clinical models of sterile inflammation.
Figure 1
CD11b+CD115+Gr1+ monocytes are required for tolerance induction to vascularized allografts. (A) Fully allogeneic vascularized cardiac grafts were 
accepted in tolerogen-treated (DST plus anti-CD40L mAb) CD11c-DTR mice (n = 10), but rejected in tolerogen-treated CD11b-DTR mice (n = 10), 
after DT administration. (B) Fully allogeneic vascularized cardiac grafts were rejected in tolerogen-treated mice that received the anti-Gr1 mAb 
RB6-8C5 (n = 10), but accepted in tolerogen-treated mice that received the anti-Gr1 mAb 1A8 (n = 10). Untreated rejecting controls were as in A. (C) 
Fully allogeneic vascularized cardiac grafts were rejected in tolerogen-treated mice that received clodronate loaded liposomes (clo-lip; n = 10) and 
in tolerogen-treated MaFIA mice (n = 10) following depletion of CD115-expressing cells. Untreated controls were as in A. Also shown are represen-
tative allograft images of H&E staining of the indicated groups at day of rejection or after 100 days of allograft survival. Original magnification, ×40.
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Results
CD11b+CD115+Gr1+ monocytes are necessary for tolerance induction. To 
identify the role of myeloid cells during the establishment of indef-
inite cardiac allograft survival, we targeted CD11c- and CD11b-
expressing recipient cells, the major cell populations of myeloid 
origin. CD11c-DTR and CD11b-DTR mice express DTR under the 
control of the CD11c and CD11b promoters, and administration 
of DT in these mice depletes CD11c+ DCs and CD11b+ monocytes, 
macrophages, and neutrophils, respectively (12, 13). Vascular-
ized BALB/c (H-2d) hearts were transplanted into fully allogeneic 
C57BL/6 (H-2b) CD11c-DTR or CD11b-DTR mice, and recipients 
were either left untreated for acute rejection or administered DST 
(1 × 107 cells i.v.) together with 500 μg anti-CD40L mAb on the day 
of transplantation for tolerance induction, as previously described 
(3). Figure 1A shows that transient depletion of CD11c-express-
ing cells prior to transplantation (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI41628DS1) did not interfere with the induction of transplan-
tation tolerance in tolerogen-treated recipients. In contrast, when 
CD11b-expressing cells were depleted (Supplemental Figure 1), tol-
erance was not induced (Figure 1A), which suggested that CD11b-
expressing cells were necessary for tolerance induction.
There are 2 main subsets of circulating monocytes that are 
characterized by their expression of CD11c and Gr1. CD11c+ 
monocytes are Gr1–, and CD11c– monocytes are Gr1+ (14). Deple-
tion of CD11c did not prevent tolerance induction (Figure 1A), 
which suggested that CD11b+Gr1+ monocytes might mediate 
tolerance induction. To investigate the tolerogenic role of Gr1+ 
monocytes during tolerance induction, depletional doses of the 
anti-Gr1 mAb clone RB6-8C5 were administered to tolerogen-
treated wild-type recipients. The results indicated that depletion 
of Gr1+ cells prevented tolerance (Figure 1B and Supplemental 
Figure 1). Since anti-Gr1 mAb clone RB6-8C5 depletes both Gr1+ 
monocytes and neutrophils under steady-state conditions (15), 
the tolerogenic role of Gr1+ monocytes was further investigated 
by specifically depleting neutrophils with the anti-Gr1 mAb clone 
1A8 (15). Consistent with previous results (16), depletion of neu-
trophils with 1A8 mAb did not interfere with tolerance induction 
(Figure 1B and Supplemental Figure 1), which suggested that 
blood circulating Gr1+ monocytes mediated the induction of 
transplantation tolerance.
To confirm that monocytes were necessary for tolerance induc-
tion, circulating monocytes and macrophages were depleted with 
clodronate-loaded liposomes 24 hours before transplantation 
(Supplemental Figure 1 and ref. 17), and allograft survival was 
monitored. Depletion of monocytes with clodronate-loaded lipo-
somes prevented tolerance induction (Figure 1C). The necessity 
of monocytes during tolerance induction was further investigated 
using transgenic MaFIA mice as recipients (18). MaFIA mice have an 
inducible Fas suicide/apoptotic system driven by the mouse CD115 
promoter after exposure to the FK-binding protein dimerizer 
AP20187. CD115 is the M-CSF receptor (M-CSFR) and is involved in 
the survival and development of monocytes and macrophages (19). 
The results showed that depletion of monocytes in tolerogen-treated 
MaFIA recipients receiving AP20187 prevented the induction of 
transplantation tolerance (Figure 1C and Supplemental Figure 1).
Anatomic localization of tolerogenic CD11b+CD115+Gr1+ monocytes. 
The anatomic location of CD115+CD11b+Gr1+ monocytes and 
their trafficking requirements were next investigated. Monocytes 
are blood-circulating cells, and the results showed an increase of 
CD115+Gr1+ monocytes in the blood of transplanted recipients 
(Figure 2A). This suggested that CD115+Gr1+ monocytes were 
being generated in the bone marrow, which was confirmed by 
the observed increase of CD115+CD11b+Gr1+ monocytes in the 
bone marrow of tolerized recipients (Figure 2B). To investigate the 
necessity of Gr1+ monocyte mobilization from the bone marrow 
during tolerance induction, we used CCR2-deficient (Ccr2–/–) mice, 
which have a 70% reduction in blood circulating Gr1+ monocytes 
and simultaneous accumulation of these cells in the bone marrow 
caused by failure to exit the bone marrow (20). Analysis of blood 
circulating CD115+Gr1+ monocytes in tolerogen-treated Ccr2–/– 
recipient mice showed no increase in these cells (Supplemental 
Figure 2A), and tolerance could not be induced (Figure 2C), which 
suggested that bone marrow mobilization of Gr1+ monocytes was 
necessary for tolerance induction. To investigate this hypothesis, 
Gr1+ monocytes were mobilized in tolerogen-treated Ccr2–/– mice 
using a single dose of AMD3100, a selective antagonist of CXCR4 
that induces rapid mobilization of bone marrow monocytes (Sup-
plemental Figure 2A and refs. 21, 22). Figure 2C indicates that 
mobilization of bone marrow Gr1+ monocytes restored indefinite 
allograft survival in tolerogen-treated Ccr2–/– recipients. Because 
treatment with AMD3100 mobilizes granulocytes in addition to 
Gr1+ monocytes from the bone marrow, wild-type bone marrow 
CD115+CD11b+Gr1+ monocytes (Supplemental Figure 2B) were 
adoptively transferred to Ccr2–/– recipients, and graft survival was 
monitored. Figure 2C indicates that transfer of wild-type bone 
marrow CD115+CD11b+Gr1+ monocytes also induced tolerance in 
tolerogen-treated Ccr2–/– recipients. Together, these results showed 
that mobilization of CD115+CD11b+Gr1+ from bone marrow to 
blood was necessary for tolerance induction.
Further analysis demonstrated an increase in CD11b+Gr1+ 
monocytes in the allografts of tolerogen-treated recipients (Figure 2D), 
suggestive of Gr1+ monocyte trafficking from the blood to the trans-
planted organ during tolerance induction. To investigate the neces-
sity of CD115+CD11b+Gr1+ monocyte trafficking into the allograft, 
we manipulated P- and E-selectins, mediators of monocyte entry into 
inflamed tissues (23), by using BALB/c hearts from P- and E-selec-
tin double-deficient (PE–/–) donors. The results indicated that PE–/– 
allografts were rapidly rejected, accompanied by a significant decrease 
in Gr1+ monocytes present in the allograft (Figure 2E and Supple-
mental Figure 2C). Blocking donor P- and E-selectin expression in the 
transplanted allograft prevented not only CD11b+Gr1+ monocytes, 
but also other cells, from trafficking into the allograft. To further 
investigate the unique role of monocytes during tolerance induction in 
the allograft, tolerogen-treated Ccr2–/– recipients were adoptively trans-
ferred with CD115+CD11b+Gr1+ monocytes from fucosyltransferase 
IV-VII double-deficient (FucTIV-VII–/–) C57BL/6 mice, and allograft 
survival was monitored. Circulating leukocytes express the ligands for 
P- and E-selectins (PSGL-1 and ESL-1) plus L-selectin, while endothelial 
cells express P- and E-selectins plus the ligands for L-selectin. Fucos-
yltransferase IV-VII is involved in the expression of selectin ligands. 
Therefore, monocytes from FucTIV-VII–/– mice are deficient in P- and 
E-selectin ligands and are prevented from tissue migration, while 
they are not deficient in L-selectin, which is necessary for lymph node 
homing (24). Adoptive transfer results indicated that unlike wild-type 
CD11b+Gr1+ monocytes, FucTIV-VII–/– Gr1+ monocytes were unable to 
migrate into the transplanted organ (Supplemental Figure 2D) and 
did not induce indefinite allograft survival (Figure 2E). This suggested 
that CD115+CD11b+Gr1+ monocyte trafficking into the grafted heart 
was necessary for tolerance induction.
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Figure 2
Anatomic localization of tolerogenic CD11b+CD115+Gr1+ monocytes. 
(A) Increase in CD115+Gr1+ blood circulating monocytes after trans-
plantation. Dot plots show the percentage of CD115+Gr1+ monocytes. 
Mice were sacrificed on day 2 after transplantation. Results represent 
mean ± SEM (n = 9 mice per group). P values were determined by 
Student’s t test. Donor DST cells were labeled with ER-Tracker blue-
white dye to exclude donor monocyte contamination. (B) Increase in 
CD115+Gr1+ bone marrow monocytes was associated with tolerance 
induction. Same parameters as in A. (C) Fully allogeneic vascular-
ized cardiac grafts were rejected by tolerogen-treated Ccr2–/– recipi-
ent mice (n = 5), but accepted in tolerogen-treated Ccr2–/– recipient 
mice receiving 1 × 106 wild-type bone marrow Gr1+ monocytes (n = 5), 
or in AMD3100-treated Ccr2–/– recipient mice (n = 5). (D) Increase in 
CD11b+Gr1+ allograft monocytes was associated with tolerance induc-
tion. Same parameters as in A. (E) Cardiac grafts were rejected by 
tolerogen-treated C57BL/6 mice receiving allografts from PE–/– BALB/c 
donors (n = 10) and by tolerogen-treated Ccr2–/– mice receiving 1 × 106 
wild-type bone marrow Gr1+ monocytes from FucTIV-VII–/– mice (n = 5), 
but accepted by tolerogen-treated Ccr2–/– mice receiving 1 × 106 wild-
type bone marrow Gr1+ monocytes (n = 5).
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Mechanisms of action of tolerogenic CD11b+CD115+Gr1+ monocytes. 
Suppressive CD11b+Gr1+ monocytes have been shown in other 
model systems to mediate their inhibitory function through 
IFN-γ–dependent pathways (25, 26). To investigate the mechanisms 
by which CD11b+Gr1+ monocytes exert their tolerogenic function 
in transplantation, CD115+CD11b+Gr1+ bone marrow monocytes 
from IFN-γ–deficient (Ifng–/–) and IFN-γ receptor–deficient (Ifngr–/–) 
mice were adoptively transferred into tolerogen-treated Ccr2–/– 
mice, and allograft survival was monitored. Tolerance was induced 
by adoptively transferred bone marrow CD11b+Gr1+ monocytes 
from Ifng–/– mice. In contrast, tolerance was not induced with 
adoptively transferred CD11b+Gr1+ bone marrow monocytes from 
Ifngr–/– mice (Figure 3A). These results suggested that CD11b+Gr1+ 
monocytes mediated their suppressive effect though IFN-γR signal-
ing. NO, one of the downstream pathways for IFN-γR, is expressed 
in CD11b+Gr1+-suppressive cells (26), and Vanhove and colleagues 
have recently described the expression of iNOS in myeloid-derived 
suppressor cells (MDSCs) that mediate transplantation toler-
ance (27). We investigated the necessity of iNOS expression by 
CD115+CD11b+Gr1+ monocytes during transplantation tolerance 
and found that tolerance was not induced in tolerogen-treated 
Ccr2–/– recipients that were transferred with iNOS-deficient (Nos2–/–) 
bone marrow monocytes (Figure 3A). Moreover, monocytes 
deficient in molecules that participate in the signaling pathway 
between IFN-γR and iNOS (STAT-1 and IRF-1) were also unable 
to restore tolerance in tolerogen-treated Ccr2–/– recipients (Figure 
3A). Immunohistochemistry showed that iNOS-expressing cells 
were present next to graft vascular endothelial cells in tolerogen-
treated recipient allografts (Figure 3B) and that CFSE-labeled 
CD115+CD11b+Gr1+ transferred monocytes expressed iNOS in 
tolerant allografts (Figure 3C). Others have previously shown that 
inflammatory monocytes require combined iNOS, arginase, and 
IL-4R expression to mediate their suppressive function (28, 29). 
CD11b+Gr1+ cells obtained from tolerized allografts upregulated 
mRNA for iNOS and arginase, but not IL-4R (Figure 3D), consis-
tent with previous results (30). In mixed leukocyte reactions per-
formed using allogeneic BALB/c (H-2d) or third-party CBA (H-2k) 
as stimulators and syngeneic C57BL/6 T cells as responders, sorted 
CD11b+Gr1+ monocytes from the allograft of tolerogen-treated 
recipients suppressed T cell proliferation in an antigen-nonspecific 
manner, whereas CD11b+Gr1+ monocytes from the bone mar-
row and the spleen of the same recipients did not suppress 
T cell proliferation (Figure 3E and data not shown). It has been 
suggested that CD115-expressing MDSCs mediate their sup-
pressive function through the programmed cell death ligand 1 
(PD-L1; ref. 31), which is necessary for transplantation toler-
ance (32, 33). Figure 3F indicated that CD11b+Gr1+ monocytes 
in tolerized allografts did not express PD-L1. Interestingly, the 
CD11b+Gr1– subset did express high levels of PD-L1, which sug-
gested that monocytes expressing PD-L1 could be involved in 
transplantation tolerance through the development of Tregs (34).
Tolerogenic monocytes are required for Treg development. Mono-
cytic suppressor cells expressing CD115 have been recently 
shown to mediate Treg development in vivo (35). To monitor 
Treg development by monocytic suppressor cells in vivo, we 
crossed CD115-GFP MaFIA mice (H-2b) with FoxP3-RFP mice 
(H-2b) to obtain mice in which Tregs could be monitored fol-
lowing monocyte depletion. BALB/c (H-2d) hearts were trans-
planted into fully allogeneic tolerogen-treated MaFIA/Foxp3 
(H-2b) recipients with or without 0.55 mg/ml AP20187 injected 
i.p. on days –5, –4, –3, –2, and –1, and allograft survival was 
monitored. Tolerance could not be induced in these recipients 
following monocyte depletion with AP20187 (data not shown). 
Treg development was investigated by examining Foxp3 expres-
sion in the blood and allograft of these recipients by flow cytom-
etry; in AP20187-treated MaFIA/Foxp3 recipients, Tregs did 
not develop with time (Figure 4, A–C). To further demonstrate 
that CD115 monocytes mediate Treg development, 1 × 106 
CD4+Foxp3– T cells were sorted, labeled with CellVue-APC, and 
adoptively transferred into 3-week-old tolerogen-treated MaFIA/
Foxp3 recipient mice with or without AP20187. CD4+Foxp3+ 
T cells could be isolated from the allografts of tolerogen-treated 
recipients 3 weeks after transfer (Figure 4D); however, monocyte 
depletion with AP20187 abrogated the ability of CD4+Foxp3– 
T cells to become Foxp3+. To further determine the role of 
CD115 monocytes in the development of Tregs, CD115-GFP 
cells from the allografts of tolerogen-treated MaFIA recipients 
with or without AP20187 were sorted 3 weeks after transplanta-
tion and cultured with CellVue-labeled CD4+Foxp3– T cells for 
72 hours, after which Foxp3 induction was monitored by flow 
cytometry. Only monocytes from the allografts of tolerant recip-
ients were able to induce Foxp3 expression (Figure 4E).
Therapeutic manipulation of monocyte precursors. To design thera-
peutic protocols for the induction of transplantation tolerance, we 
used the MDP, which gives rise to monocytes, macrophages, con-
ventional DCs, and plasmacytoid DCs; conversely, the common 
DC precursor (CDP) gives rise to DCs and plasmacytoid DCs, but 
not monocytes (36–38). MDP or CDP were adoptively transferred 
to tolerogen-treated Ccr2–/– recipients, and allograft survival was 
monitored. Adoptively transferred MDP, but not CDP, gave rise 
to blood circulating monocytes (Figure 5A). Tolerance was not 
induced in tolerogen-treated Ccr2–/– recipients that received CDP 
(Figure 5B). In contrast, tolerance was induced in Ccr2–/– recipients 
that received MDP, which suggested that manipulation of CD115-
expressing monocyte precursors may represent a novel therapeutic 
approach for the induction of transplantation tolerance.
Discussion
We identified CD11b+CD115+Gr1+ suppressive bone mar-
row monocytes as tolerance-inducing cells that accumulated 
in cardiac allografts early after transplantation and mediated 
the development of indefinite allograft survival. Identifying 
CD11b+CD115+Gr1+ monocytes as suppressive cells that medi-
ate transplantation tolerance contributes to the resolution of 
the longstanding quest to find a tolerogenic cell of myeloid ori-
gin. Past evidence suggested that a variety of MHC II+ myeloid 
cells presumed to be DCs were required for tolerance (11), yet, 
despite an exhaustive search for a tolerogenic DC subpopulation 
in transplantation (39), accumulating evidence supports the idea 
that the same DC subset is implicated in both immunity and 
tolerance (40). However, a recently described myeloid-derived 
cell subpopulation (41) seems to favor tolerance via impairing 
T lymphocyte reactivity by inhibiting only activated T lympho-
cytes (42), while favoring the development of Tregs (35). These 
tolerogenic cells, the MDSCs, correspond phenotypically and 
functionally to the cells that we have characterized here. These 
CD11b+CD115+Gr1+ bone marrow monocytes appear to be dif-
ferent from the novel monocyte reservoir population previously 
identified in the spleen (43), since tolerance could be induced in 
recipient mice following splenectomy (data not shown).
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Figure 3
Mechanisms of action of tolerogenic CD11b+CD115+Gr1+ monocytes. (A) Cardiac allografts were accepted by tolerogen-treated Ccr2–/– mice 
receiving 1 × 106 bone marrow Gr1+ monocytes from Ifng–/– mice, but rejected by mice receiving 1 × 106 bone marrow Gr1+ monocytes from Ifngr–/–, 
Stat1–/–, Irf1–/–, or Nos2–/– mice (n = 5 per group). (B) Representative images of immunohistochemical analysis of iNOS+ cells around graft endothelial 
cells 2 days after transplantation (n = 5 mice per group). Original magnification, ×40. (C) Fluorescent immunohistochemistry of CFSE-labeled adop-
tively transferred monocytes stained with iNOS in the allograft (n = 2 ± 0.3 cells/vessel; 20 vessels/heart; n = 3 mice). Original magnification, ×40. 
(D) Real-time RT-PCR of iNOS, arginase, and IL-4R expression in CD11b+Gr1+ monocytes in the allograft 2 days after transplantation. Data are 
representative of 3 independent experiments; SEM of PCR triplicates are shown. P values were determined by Student’s t test. (E) Freshly isolated 
CD3+CD4+ T cells from C57BL/6 mice were sorted and labeled with CFSE, and 5 × 104 cells/well were cultured with CD11b+Gr1+ allograft monocytes 
(2.5 × 104 cells/well) in the presence of BALB/c or CBA APC (2.5 × 104 cells/well) for 72 hours. Proliferation of T cells was measured by CFSE dilu-
tion. Percentages of divided and undivided cells are shown. Data are representative of 3 independent experiments. (F) Expression of PD-L1 and 
MHC-II in CD115+Gr1+ and CD115+Gr1– monocytes in the allografts of tolerant mice. Mice were sacriﬁced on day 2 after transplantation. Results 
are mean ± SEM (n = 5 mice). Donor DST cells were labeled with ER-Tracker blue-white dye to exclude donor monocyte contamination.
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Historically, transplant immunologists have attempted to 
develop novel tolerogenic protocols by targeting adaptive immune 
response mechanisms, based on the observation that T cells are 
both necessary and sufficient to induce allograft rejection. These 
mechanisms involve deletion of activated T cells (44) and develop-
ment of Tregs (45). However, tolerance-inducing protocols cannot 
rely only on lymphoablative therapy (46, 47). Deletion of activated 
T cells is necessary, but not sufficient, for induction of transplan-
tation tolerance, since T cells from tolerant recipients are able to 
reject allografts adoptively transferred into new recipients within 
3 weeks after transplantation (48). On the other hand, antigen-spe-
cific Tregs do not seem to participate during the early phase of tol-
erance induction (49), as it takes 3 weeks for Tregs to fully develop 
in the periphery of tolerant recipients (50, 51). These observations 
suggest that additional mechanisms of early immune regulation 
must exist that protect the allograft from being acutely rejected by 
day 10 after transplant. We hypothesize that in addition to previ-
ously described adaptive mechanisms necessary for transplanta-
tion tolerance, mechanisms that occur during the innate immune 
response are also required for the induction of indefinite allograft 
survival; moreover, we propose that in an ischemic/inflamed tissue 
environment, as a consequence of the surgical procedures intrin-
sic to transplantation, suppressive monocytes protect the allograft 
from multiple rejection pathways.
Recent advances in our understanding of how the immune 
response is influenced by a variety of antigen-nonspecific events 
have highlighted the participation of the innate immune system 
in solid organ transplantation and its critical role in shaping the 
adaptive immune response (52). In this respect, there is increasing 
interest in investigating the regulation of the immune response by 
nonlymphoid cells in transplantation (53), and monocytes seem 
to play an important role in non-self allorecognition during the 
innate immune response (54). Inflammatory Gr1+ monocytes are 
excellent candidates to mediate transplantation tolerance induc-
tion for several reasons. In contrast to CD11chi MHC class II+ 
DCs, which are absent in the blood (55), significant numbers 
of Gr1+ monocytes constantly circulate in the blood, expressing 
intermediate levels of CD11c and MHC class II (56), are rapidly 
recruited to inflamed tissues (57, 58). Once in the inflamed tis-
sue, Gr1+ monocytes become antiinflammatory monocytes in the 
presence of IFN-γ (59, 60). We observed that CD115+CD11b+Gr1+ 
monocytes mediated tolerance though IFN-γ–dependent path-
ways. Although the protective role of IFN-γ in transplantation 
tolerance remains controversial, accumulating evidence indicates 
that the IFN-γ signaling pathway is necessary to achieve indefinite 
allograft survival. Tolerance to vascularized heart allografts is not 
induced in Ifng–/– recipient mice because of exaggerated expan-
sion of alloreactive effector T lymphocytes (61). These tolerogenic 
effects of IFN-γ occur within the allograft, which may explain the 
necessity of CD11b+CD115+Gr1+ bone marrow cells in this ana-
tomic compartment. With regard to the protective role of IFN-γ in 
the allograft, Heslan et al. described that IFN-γ and NO synthase 
gene expression are upregulated in infiltrating cells of tolerated 
heart allografts (62), and this in turn is associated with Treg devel-
opment at the transplanted site (63). Similarly, Wood and col-
leagues reported that development of alloantigen-reactive Tregs 
is impaired in the absence of IFN-γ and iNOS within the allograft 
(64), and, more recently, Bushell and colleagues reported that allo-
antigen-activated CD4+ T cells cultured in the presence of IFN-γ 
promotes the generation of Foxp3+ Tregs capable of preventing 
allograft rejection following adoptive transfer (65, 66). Therefore, 
expression of IFN-γ and iNOS in the transplanted graft precedes 
Treg development and the induction of transplantation tolerance. 
Consistent with this hypothesis, Vanhove and colleagues recently 
reported that iNOS-expressing MDSCs are necessary for indefi-
nite allograft survival, are required to stimulate IFN-γ secretion of 
Tregs, and are present tolerant kidney allografts (27). This seminal 
work from Vanhove and colleagues also suggests that MDSCs are 
needed during the maintenance phase of transplantation toler-
ance (27), which highlights the importance of investigating the 
role of suppressive monocytes over time.
We conclude that bone marrow–derived CD11b+CD115+Gr1+ 
monocytes are necessary for transplantation tolerance and that 
manipulation of MDP suggests possible therapeutic approaches 
using these precursor cells; our results also indicate the need to 
identify these cells in humans. Manipulation of monocyte devel-
opment has already demonstrated promising results during sterile 
inflammation in mice. Geissler and colleagues recently reported 
that differentiation of monocytes in the presence of IFN-γ results 
in the development of tolerogenic macrophages in vivo with 
T cell–suppressive function (67). Similar results have been obtained 
with human cells in vitro, in which IFN-γ mediated development 
of tolerogenic DCs from blood monocytes, with the ability to 
promote Treg development (68). We suggest that there may be 
at least 2 populations of tolerogenic monocytes that control the 
immune response: inflammatory Gr1+ monocytes that suppress 
antigen-nonspecific responses early after transplantation, and 
antiinflammatory Gr1– monocytes that promote Treg develop-
ment though PD-L1 expression. Potential clinical applications of 
CD11b+CD115+Gr1+ cells in certain pathological conditions, such 
as cancer, infectious diseases, sepsis, trauma, bone marrow trans-
plantation, and autoimmunity, have previously been suggested (69). 
Here we extend their use to transplantation to promote induction 
of indefinite allograft survival, and although their development 
in other tolerance-inducing protocols needs to be further investi-
gated, evidence suggests that suppressive monocytes are generated 
with common immunosuppressive therapeutics, such as glucocor-
ticoids (70). In this respect, new strategies are directed to develop 
suppressive cells in vitro for immunotherapy in transplantation 
Figure 4
Tolerogenic monocytes are required for Treg development. (A) Dot 
plots show the percentage of Foxp3+ and CD115+ cells in the blood 
of tolerogen-treated MaFIA/Foxp3 recipients with and without AP20187 
over time (n = 5 mice per group). (B) Bar graphs indicate the percentage 
of CD4+Foxp3+ T cells or CD115+Gr1+ monocytes in tolerogen-treated 
MaFIA/Foxp3 recipients with and without AP20187 treatment over time. 
Results represent mean ± SEM. P values were determined by Student’s 
t test. (C) Dot plots show the percentage of Foxp3+ and CD115+ cells 
in the allografts of tolerogen-treated MaFIA/Foxp3 recipients with and 
without AP20187 treatment (n = 5 mice per group) 3 weeks after trans-
plantation. (D) Dot plots show induction of Foxp3 in vivo. CD4+Foxp3– 
T cells (1 × 106) were labeled with CellVue and adoptively transferred to 
tolerogen-treated MaFIA/Foxp3 recipient mice on the day of the trans-
plant. Induction of CD4+Foxp3+ T cells was observed in the allografts of 
recipient mice 3 weeks after transfer (n = 5 mice per group). (E) Dot plots 
show induction of Foxp3 in vitro. CD115+ cells obtained from allografts 
of tolerogen-treated MaFIA recipients (2.5 × 104 cells/well) 3 weeks 
after transplantation were sorted and cultured with CD4+Foxp3– T cells 
(5 × 104 cells/well). Induction of CD4+Foxp3+ T cells was observed after 
72 hours. Data are representative of 3 independent experiments.
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(71, 72). Interestingly, Bronte and colleagues have recently identi-
fied CCAAT enhancer–binding protein β (C/EBPβ) as a molecu-
lar target that can be exploited to generate CD11b+Gr1+ cells with 
high suppressive function, and have experimental evidence that 
culturing bone marrow precursors with GM-CSF plus IL-6 gener-
ates monocytic CD11b-expressing MDSCs that prolong islet graft 
survival indefinitely (73).
Methods
Animals. BALB/c and C57BL/6 (Ccr2–/–, Ifng–/–, Ifngr–/–, Stat1–/–, Irf1–/–, Nos2–/–), 
CD11c-DTR B6.FVB-Tg (Itgax-DTR/GFP), CD11b-DTR B6.FVB-Tg (Itgam-
DTR/GFP), and Foxp3-RFP mice 8–12 weeks of age were purchased from 
The Jackson Laboratory. The C57BL/6-Tg (Csf1r-EGFP-NGFR/FKBP1A/
TNFRSF6) 2Bck/J MaFIA mice were from D. Cohen (University of Kentucky, 
Lexington, Kentucky, USA). PE–/– and FucTIV-VII–/– mice were a gift from 
J. Lowe (Case Western University, Cleveland, Ohio, USA). All experiments 
were performed with age- and sex-matched mice in accordance with Institu-
tional Animal Care and Utilization Committee–approved protocols.
In vivo cell depletion. CD11c-DTR recipients were injected i.p. with 5 ng/g 
body weight of DT (Sigma-Aldrich) to deplete DCs (12), and CD11b-DTR 
recipients were treated with 2 doses of DT at 25 ng/g body weight 48 hours 
apart to deplete monocytes and macrophages (13), 24 hours before trans-
plantation. CD115 MaFIA mice were injected with AP20187, a gift from 
Ariad Pharmaceuticals. Lyophilized AP20187 was dissolved in 100% etha-
nol at a concentration of 13.75 mg/ml (1 nM) stock solution and stored at 
–20°C. MaFIA mice received 0.55 mg/ml of AP20187 containing 4% ethanol, 
10% PEG-400, and 1.7% Tween-20 in water. We injected 10 mg/kg AP20187 
i.p. on days –5, –4, –3, –2, and –1. For granulocyte depletion, anti-Gr1 mAb 
clone RB6-8C5 (from R. Coffman, DNAX, Palo Alto, California, USA) was 
administered (0.5 mg i.v. on days –3, –2, and –1 relative to transplantation; 
ref. 15). Neutrophil depletion was induced with anti-Gr1 mAb clone 1A8 
(BioXcell) at 0.5 mg i.p. on days –3, –2, and –1 relative to transplantation 
(15). Monocyte/macrophage depletion was performed by i.v. injections of 
250 μl liposomes containing clodronate, as previously described (17).
Reagents. anti-CD40L mAb (clone MR1) was from R. Noelle (Dartmouth 
University, Lebanon, New Hampshire, USA) and purified over protein G or 
protein A columns (Amersham Pharmacia Biotech). For flow cytometry, 
anti-CD11b, anti-CD115, anti–Ly-6C/6G (Gr1), anti–C-Kit, anti-FLT3, anti–
TER-119, anti–PDCA-1, anti-B220, anti-CD19, anti-CD4, and anti-CD3 were 
purchased from eBioscience. Clodronate-loaded liposomes were prepared as 
described previously (13). For bone marrow mobilization, AMD3100 (Sigma-
Aldrich) was injected s.c. at 5 mg/kg on day –1 relative to transplantation.
Vascularized heart transplantation. BALB/c hearts were transplanted as fully 
vascularized heterotopic grafts into C57BL/6 mice as described previously 
(74). Recipient mice were treated with DST (1 × 107 donor splenocytes i.v.) 
on the day of the transplant together with 500 μg anti-CD40L mAb for tol-
erance induction (3). DST cells were labeled with ER-Tracker blue-white dye 
(Invitrogen) to exclude donor monocyte contamination. Graft function was 
monitored every other day by abdominal palpation. Untreated control mice 
received hamster IgG in PBS. Rejection was defined as complete cessation of 
a palpable beat and confirmed by direct visualization at laparotomy.
Cell purification and adoptive transfer. Mice were sacrificed, and the spleen 
and bone marrow were removed and gently dissociated into single-cell sus-
pensions. Red blood cells were removed by using hypotonic ammonium 
chloride potassium (ACK) lysis buffer. Cells were placed in complete RPMI 
medium (RPMI 1640 supplemented with 10% FCS, 1 mM sodium pyru-
vate, 2 mM l-glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin, 1× 
nonessential amino acids, and 2 × 10–5 M 2-ME). Bone marrow monocytes 
were stained with 5 μM CFSE (Invitrogen) or CellVue (Sigma-Aldrich) and 
isolated by sorting on a MoFlo cell sorter (DakoCytomation) to greater than 
99% purity, excluding dead cells with DAPI. CD115+CD11b+Gr1hi sorted 
monocytes (2 × 105) were injected i.v. in 300 μl PBS at the indicated times.
Isolation of cardiac allograft leukocytes. Mouse hearts were rinsed in situ with 
HBSS with 1% heparin. Explanted hearts were cut into small pieces and digested 
Figure 5
Therapeutic manipulation of tolerogenic monocytes. (A) Dot plots show the gating scheme and percentages of MDP and CDP in wild-type bone mar-
row (top). CD45.1 MDP or CDP was adoptively transferred into CD45.2 mice (bottom). Dot plots indicate that adoptively transferred MDP gave rise 
to blood circulating CD115+ monocytes, whereas CDP did not. Representative data from 4 independent experiments are shown. Each experiment 
included at least 3 separately analyzed mice. (B) Fully allogeneic vascularized cardiac grafts were rejected by tolerogen-treated Ccr2–/– recipient mice 
receiving 2 × 103 bone marrow CDP (n = 5), but accepted by tolerogen-treated Ccr2–/– recipient mice receiving 2 × 103 bone marrow MDP (n = 5).
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for 40 minutes at 37°C with 400 U/ml collagenase IV (Sigma-Aldrich), 10 mM 
HEPES (Cellgro), and 0.01% DNase I (MP Biomedicals) in HBSS (Cellgro). 
Digested suspensions were passed through a nylon mesh and centrifuged, 
and the cell pellet was resuspended in 5 ml 45.5% Nycodenz solution (Sigma-
Aldrich). Complete DMEM (3 ml) was added to the top of the Nycodenz, and 
gradient centrifugation was performed (1,700 g for 15 minutes at 4°C). The 
cells at the interface were recovered, washed with complete DMEM, stained, 
and analyzed by flow cytometry (BD LSR-II; BD Biosciences).
In vitro suppression assay. C57BL/6 mice were sacrificed, spleens were removed 
and gently dissociated into single-cell suspensions, and red blood cells were 
removed using hypotonic ACK lysis buffer. Splenocytes were enriched for 
CD4+ T cells using a CD4+ negative selection kit (R&D Systems). Cells were 
stained with allophycocyanin-conjugated anti-mouse CD3 and PE-conju-
gated anti-mouse CD4 mAbs for 30 minutes on ice. CD3+CD4+ T cells were 
sorted using FACSVantage DiVa (BD Biosciences) or MoFlo (DakoCytoma-
tion). The purity of cells was greater than 99%. Gamma-irradiated (15 Gy) 
BALB/c (H-2d) and CBA (H-2k) splenocytes were depleted of T cells by nega-
tive selection with Mouse pan T Dynabeads according to the manufacturer’s 
protocol (Dynal) and used as stimulator cells. Purified CD11b+Gr1+ allograft 
cells (2.5 × 104 cells/well) were cultured with BALB/c or CBA T cell–deplet-
ed splenocytes (2.5 × 104 cells/well), and CFSE-labeled (5 μM; Invitrogen) 
C57BL/6 responder CD3+CD4+ T cells (5 × 104 cells/well) in a final volume of 
250 μl complete RPMI medium in U-bottom 96-well plates (Corning). Cells 
were cultured for 3 days at 37°C in a 5% CO2 incubator. T cell proliferation 
was measured by flow cytometric analysis of CFSE dilution.
Quantitative RT-PCR. Total RNA was extracted from purified cells with 
TRIzol solution (Invitrogen). Reverse transcription was carried out using 
the Omniscript reverse-transcription system (Qiagen) and random primers. 
Quantitative PCR was performed with the LightCycler system (Roche) and 
the SYBR Green PCR kit (Qiagen). All experiments were done at least 3 sepa-
rate times, and expression of specific genes was normalized and expressed as 
percentage relative to housekeeping genes (cyclophilin A or GAPDH).
Immunofluorescence microscopy. Transplanted hearts were harvested, sub-
divided, frozen directly in OCT (Fisher), and stored at –80°C in prepara-
tion for immunological studies. Sections of 8 μm were cut using a Leica 
1900CM cryomicrotome, ﬁxed, and mounted with Gel/Mount (Biomeda) 
on polylysine-coated slides. Rabbit anti-mouse iNOS was purchased from 
Abcam. Phycoerythrin-conjugated rat anti-mouse iNOS was purchased 
from Jackson Immunoresearch. All slides were mounted with Vectashield 
(Vector Laboratories) to preserve fluorescence. Images were acquired with a 
Leica DMRA2 fluorescence microscope (Wetzlar) and a digital Hamamatsu 
charge-coupled device camera. Separate green, red, and blue images were 
collected and analyzed with Openlab software (Improvision).
Flow cytometry. Cell washes and Ab dilutions were performed in PBS plus 
1% BSA at 4°C. Flow cytometric analysis was performed on LSR II (BD 
Biosciences) and analyzed with FlowJo (Tree Star). Results are expressed as 
percentage of cells staining above background, and mAbs were titered at 
regular intervals during the course of these studies to ensure that saturat-
ing concentrations were used.
Statistics. Differences between graft survival rates were assessed by 
Kaplan-Meier survival analysis with StatView software. Differences 
between cell numbers and percentages were assessed by 2-tailed Student’s 
t test analysis with StatView software. P values of 0.05 or less were consid-
ered statistically significant.
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